Understanding the Market | XTALPI rose over 4% recently after being included in the FTSE China Small Cap Index, with its AI pharmaceutical commercialization capabilities being validated

XTALPI rose over 4%, as of the time of writing, up 4.56%, reported at HKD 11.92, with a turnover of HKD 2.259 billion. In terms of news, recently, FTSE Russell updated the semi-annual adjustment list for the FTSE Global Equity Index Series for September. Among them, XTALPI was included in the FTSE China Small Cap Index. The related adjustments officially took effect after the market closed on September 19. Analysts pointed out that inclusion in an international index means broader capital attention and liquidity premium. CITIC Securities' research report indicated that XTALPI achieved profitability for the first time, securing nearly USD 6 billion in orders, further validating its AI pharmaceutical commercialization capabilities. In the first half of this year, benefiting from cooperation with DoveTree, the company achieved revenue of RMB 517 million, a year-on-year increase of 403.8%; adjusted net profit was RMB 141.6 million, achieving half-year profitability for the first time, and made positive progress in embodied intelligence (smart spoon) and Multi-Agent aspects